Aerocrine: The latest share price. Save Reset. Aerocrine (AERO). kr n/a. % kr Today’s Low & High; n/a / n/a. Open / Previous Close; n/a / Aerocrine AB researches, developes, and sells systems and products for measuring airway inflammation. The Company has developed a method for diagnosing. Aerocrine Ab (GM) historical price data and ACNOY charts. Free real-time prices, trades, and chat.
|Published (Last):||25 October 2009|
|PDF File Size:||11.84 Mb|
|ePub File Size:||13.54 Mb|
|Price:||Free* [*Free Regsitration Required]|
This encompasses all issued stock – restricted and free trading. Based on the above, the Board unanimously recommends the Aerocrine shareholders to accept the Offer. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.
The Opinion is attached to this statement.
Statement by the Board of Directors of Aerocrine in relation to Circassia’s public cash offer
The change of control provisions would be triggered if a party would acquire shares representing more than 40 per cent of the votes of Aerocrine. Aefocrine statement shall in all respects be governed by and construed in accordance with substantive Swedish law.
About Us Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The Board has taken into account a number of factors that the Board has considered relevant to the assessment of the Offer.
Circassia has not xnd any other non-public information that could reasonably be expected to affect the price of the Aerocrine share in connection with the review. The founders of Aerocrine emerged from the highly prestigious Karolinska Institute in Sweden where they were the first to identify nitric oxide NO as a marker of inflammation.
The total value of the Offer, based on , shares in Aerocrine, amounts to Pricew 1,, The acceptance period of the Offer is expected to commence on May 19, and expire on June 11,subject to any extensions. Aerocrine has taken this significant discovery from laboratory to listed company and is now established in some of the worlds largest markets.
This statement has been made in a Swedish and English version. The total market value of a company.
Aerocrine AB ser B
The Board assumes that this description is accurate and has in relevant aspects no reason to take a different view. Aerocine does not hold any own shares in treasury. This press release may not be published, distributed, transmitted or otherwise sent into the United States of America including its territories and possessions, every State in the United States and the District of ColumbiaAustralia, Canada, Japan or South Africa or any other state or jurisdiction in which such release, publication or distribution would be unlawful.
Circassia is offering SEK 2. The Board has, at the written request of Circassia, permitted Circassia to carry out a confirmatory due diligence review of Aerocrine in connection with the preparation of the Offer.
Aerocrine AB ser B – Latest price – Charts, news and recommendations
Disputes arising from this statement shall be settled exclusively by Swedish courts. Best deals to access real time data! However, if the entire amount of the loan is prepaid, the penalty would be reduced by interest and milestone payments already paid. This press release does not constitute an extension into the United States or any other jurisdiction of the Offer mentioned in this press release. Calculated by taking the current stock price and subtracting yesterday’s closing price.
Both are highly reliable and effective tools to assist in the diagnosis and control of airways disease. The Information was submitted for publication on May 15, at Take the number of shares outstanding and an by current price. In case prives any discrepancies between the Swedish and the English text, the Swedish text shall prevail.
Measuring airways inflammation helps doctors to diagnose, monitor and optimise therapy for people with inflammatory airway diseases.
Circassia has reserved the right to waive these and other conditions for completion of the Offer.
Sales figure represents last 12 months as of March 31, The Offer represents a multiple of 8. Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. Price change is the difference in price compared to the previous close.
The information set out in this press release is announced in accordance with the Swedish Securities Markets Act and the Takeover Rules. The most prevalent stock types are common, preferred, restricted, and fund. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June This means that in case Circassia completes the Offer, even if such completion is made at a lower acceptance level than more than 90 per cent of the shares, the payment under the credit agreement may be accelerated and the prepayment penalty may become due and payable.